Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.

Autor: Stougaard EB; Complication Research, Steno Diabetes Center Copenhagen, Herlev, Denmark., Rossing P; Complication Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Herlev, Denmark., Vistisen D; Clinical Epidemiology, Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Public Health, University of Copenhagen, Herlev, Denmark., Banks P; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA., Girard M; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA., Davies MJ; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA., Persson F; Complication Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jul; Vol. 25 (7), pp. 1874-1882. Date of Electronic Publication: 2023 Mar 20.
DOI: 10.1111/dom.15047
Abstrakt: Aims: Sotagliflozin (SOTA) as adjunct to insulin therapy improves glycemic control, reduces body weight and blood pressure, and increases time in range in adults with type 1 diabetes (T1D). SOTA demonstrated CV and kidney benefits in high-risk adults with type 2 diabetes. These potential benefits using SOTA for T1D may collectively outweigh the risk of diabetic ketoacidosis. The present analysis estimated the risk of CVD and kidney failure in adults with T1D treated with SOTA.
Materials and Methods: Participant-level data were used from the inTandem trials evaluating 2980 adults with T1D randomized to once-daily placebo, SOTA 200 mg, or SOTA 400 mg for 24 weeks. For each participant, the cumulative risks of developing CVD and kidney failure were estimated using the Steno T1 Risk Engine. A subgroup analysis was performed in participants with BMI ≥ 27 kg/m 2 .
Results: SOTA significantly reduced the predicted 5- and 10-year CVD risk in the SOTA 200 and 400 mg pooled group with a relative change in the SOTA group compared to the relative change in the placebo group of (mean [95%-confidence interval (CI)]) -6.6 (-7.9, -5.3) % and -6.4 (-7.6, -5.1) % (p < 0.0001 for both) respectively. For the 5-year ESKD risk there was a significant reduction with a relative change of -5.0 (-7.6, -2.3) % (p = 0.0003). Similar results were observed with the individual doses and in participants with BMI ≥ 27 kg/m 2 .
Conclusion: This analysis provides additional clinical results that may positively balance the benefit/risk assessment of SGLT inhibition use in T1D.
(© 2023 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: